- Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Most popular

All articles

Show search box
Holoclar – EU’s first stem cell therapy

Holoclar – EU’s first stem cell therapy

European Commission on 17th February 2015 has given conditional marketing authorization of unprecedented medicine in EU. The active substance of Holoclar is the patient’s own limbal stem cells. It is a type of advanced therapy product called a tissue engineered product. It will be implanted to pati... Read more
Tags stem cells , Holoclar , European Medicines Agency